Phase III trials now collect an average of 5.9 million data points per protocol, up 11% annually since 2020, and that volume is exactly why the FDA’s January 2025 draft guidance on AI in regulatory decision-making matters more than sponsors may have registered. The guidance doesn’t ask whether you use AI; it asks whether you can defend it. Specifically, it introduces a credibility assessment framework that ties the scrutiny level applied to any AI model directly to the consequence of that model being wrong.
The practical weight of that framing lands hardest on oversight functions: risk-based monitoring, anomaly detection, data quality flagging. These are the places sponsors have moved fastest to deploy AI, and they are also the places where a flawed model most directly affects what goes into a regulatory submission. Under the draft framework, sponsors bear the documentation burden. If an AI model informed a decision that touched patient safety data or site selection, the question isn’t whether it worked; it’s whether the sponsor can show the FDA how they assessed its fitness for that specific use before they used it.
The enforcement signal arrived in April 2026, when the FDA issued what is widely reported as its first warning letter explicitly citing AI misuse, directed at a pharmaceutical manufacturer in Michigan. That letter involved manufacturing rather than clinical trials, but the underlying issue, deploying AI in a regulated context without adequate validation, is structurally identical to risks building inside trial operations teams. The FDA has now demonstrated it will act; sponsors who treated the January 2025 draft as a distant policy document have less runway than they assumed.
The concrete next step for any sponsor actively using AI in monitoring or data review is straightforward: map each AI tool to the credibility assessment categories in the draft guidance now, before finalization locks in expectations. Waiting until the guidance is final to begin that inventory means starting the documentation process after the standard is set, which is the position no sponsor wants to be in when the next inspection occurs.
Source link: https://www.eclinicalsol.com/blog/what-does-the-fdas-risk-based-approach-to-ai-guidance-mean-for-sponsors/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
